002872 ST天圣制药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-1.753-4.355-4.065-2.939-18.770
总资产报酬率 ROA (%)-1.301-3.220-2.974-2.004-12.188
投入资产回报率 ROIC (%)-1.469-3.701-3.376-2.320-14.633

边际利润分析
销售毛利率 (%)44.92447.08356.57441.26429.093
营业利润率 (%)-9.617-16.152-13.955-8.279-41.600
息税前利润/营业总收入 (%)-8.147-15.196-12.495-6.170-41.704
净利润/营业总收入 (%)-9.216-16.176-15.083-9.820-41.038

收益指标分析
经营活动净收益/利润总额(%)151.407101.621125.389141.25731.842
价值变动净收益/利润总额(%)-43.668-2.123-5.850-8.3950.481
营业外收支净额/利润总额(%)0.5111.214-0.701-12.0266.404

偿债能力分析
流动比率 (X)1.6681.5201.4691.9471.441
速动比率 (X)1.3821.2211.2341.6841.124
资产负债率 (%)25.78625.44526.36026.9480.345
带息债务/全部投入资本 (%)10.4786.8267.15511.13616.035
股东权益/带息债务 (%)789.0421,244.1261,188.356729.639479.127
股东权益/负债合计 (%)287.320292.414278.749270.393186.301
利息保障倍数 (X)-5.361-13.169-9.164-5.053-15.204

营运能力分析
应收账款周转天数 (天)94.73490.60092.643182.129203.091
存货周转天数 (天)155.622156.822174.443171.872123.307